Research Paper Volume 11, Issue 10 pp 3280—3297
Brain-specific NRSF deficiency aggravates dopaminergic neurodegeneration and impairs neurogenesis in the MPTP mouse model of Parkinson’s disease
Figure 6. Early assessment of neurogenesis. (A) Immunohistochemical staining of BrdU in the SVZ, 7 days after MPTP/saline treatment. Scale bar: 200 μm. Quantification of BrdU-positive cells is shown in the right panel. Data are means ± SEM. Data were analyzed by one-way ANOVA. **p < 0.01, vs saline-treated control; ##p < 0.01, vs MPTP-treated WT mice. N = 3–4. (B–D) Immunofluorescence staining of BrdU (red) and Nestin, Sox2, or GFAP (green) in the SVZ. Scale bar: 100 μm.